ProfileGDS5678 / 1440729_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 54% 54% 54% 57% 50% 55% 56% 54% 52% 53% 54% 51% 56% 54% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3810954
GSM967853U87-EV human glioblastoma xenograft - Control 23.3255754
GSM967854U87-EV human glioblastoma xenograft - Control 33.3554354
GSM967855U87-EV human glioblastoma xenograft - Control 43.3817757
GSM967856U87-EV human glioblastoma xenograft - Control 53.1424250
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.472155
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.4990956
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3137854
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.2620952
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.28753
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.3267554
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.180851
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.4287756
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3256454